INTELLIGENCE BRIEF 03

Bioactive Peptides May Be the Next Functional Platform Hiding Inside Protein

The protein conversation may shift from how much protein a product contains to what functional information its protein system can release.

Why It Matters

Protein has established consumer meaning around muscle, strength, recovery, satiety, and general nutrition. Bioactive peptides could extend protein science beyond these familiar benefits. Specific amino-acid sequences released from proteins have demonstrated biological activity across laboratory, preclinical, and some human studies, creating interest in their potential roles in blood-pressure regulation, metabolic health, gastrointestinal function, and immune support.

Peptides are already visible across skincare, collagen nutrition, performance products, and peptide-based medicines, but these associations remain fragmented and category-specific. Consumers may recognize the term without understanding peptides as a broader functional platform potentially connected to different biological outcomes.

This creates both an opportunity and a translation challenge. The most immediate commercial pathway may be to use specific peptide functions to augment and differentiate benefits that protein already has permission to support. Over time, validated peptide systems could create credible pathways into more specific functional outcomes that consumers do not currently associate with protein.

Viewed this way, bioactive peptides introduce a new design dimension for protein innovation. The conversation could gradually shift from how much protein a product contains to what functional information its protein system can release.

What We Know

How Peptides Are Released. – Proteins are chains of amino acids folded into larger structures. Within those structures are shorter peptide sequences that may remain inactive or inaccessible until they are released from the parent protein. Release can occur during gastrointestinal digestion, controlled enzymatic hydrolysis, microbial fermentation, or certain food-processing conditions.

Sequence, Structure, and Concentration Determine Biological Activity. – The biological activity of a peptide depends on its amino-acid sequence, structure, and concentration. Different peptides may interact with enzymes, receptors, microorganisms, minerals, or cellular signaling pathways.

Release Alone Does Not Establish Functional Relevance. – A peptide must become accessible from the protein and food matrix, remain sufficiently stable, and reach its intended site of action at a meaningful concentration. Peptides acting within the gastrointestinal tract may not require absorption into circulation. Those intended to produce systemic effects must also survive digestion, cross the intestinal barrier, and remain active long enough to reach the relevant biological target.

Protein Source Alone Does Not Determine Functional Performance. – The method used to release peptides, processing conditions, food matrix, effective dose, storage stability, and what happens during digestion all influence which peptides are present, whether they remain active, and how effectively they are delivered. Hydrolysis can also introduce formulation challenges by affecting bitterness, solubility, texture, and other product properties.

Developing a bioactive-peptide system therefore requires control across the full pathway: **Protein source → Peptide release → Bioaccessibility → Delivery to the site of action → Biological Response.** The opportunity is not simply to find a protein associated with a desired benefit. It is to identify the relevant peptide sequences, release them consistently, and design a food or beverage system that delivers them in an active, effective, and sensorially acceptable form.

Peptides Are Already Fundamental to Human Biology and Medicine. – GLP-1 and insulin are peptides produced by the body, while medicines such as semaglutide demonstrate how peptide-based molecules can target specific biological pathways. These familiar examples do not establish the efficacy of food-derived bioactive peptides, but they illustrate an important principle: specific amino-acid sequences can carry biological signals capable of producing targeted effects. Food-derived peptides from dairy, egg, plant, marine, meat, and other protein sources have demonstrated biological activity in laboratory and preclinical studies. Human evidence is more concentrated, with selected dairy-derived peptides and collagen peptides studied for outcomes including blood-pressure regulation, skin health, and joint function. Evidence supporting one peptide, hydrolysate, dose, or application cannot be generalized to other peptide systems.

The Remaining Evidence Gap. – A central gap remains between identifying activity in a laboratory assay and demonstrating a meaningful benefit in a finished product. Peptides may be transformed during processing or digestion, fail to reach the intended site of action, or be delivered at concentrations below those used in experimental studies. Protein hydrolysates also contain complex mixtures, making it difficult to determine which peptides are responsible for an observed effect and whether the composition can be reproduced consistently. The strongest evidence will connect a defined peptide or reproducible peptide profile with its effective dose, delivery pathway, and biological response in people.

What It Could Mean for Food & Beverage

More Precisely Designed Protein Benefits. – The most immediate applications may strengthen outcomes that protein already has permission to support. Targeted peptide systems could differentiate products designed for muscle maintenance, recovery, satiety, connective-tissue support, and healthy aging by moving from general protein delivery toward more specific functional performance.

New Outcome Spaces. – Validated peptides could create pathways into cardiovascular, metabolic, gastrointestinal, immune, and other benefits not conventionally associated with protein. In these applications, protein may serve as the source of the peptide without remaining central to the consumer proposition. Success will depend on credible evidence for the specific peptide, outcome, dose, and delivery system.

Sequence-Informed Ingredient Platforms. – Protein ingredients could increasingly be characterized by the peptide sequences they contain and the conditions required to release them, alongside source, amino-acid composition, digestibility, and technical functionality. Fermentation, controlled hydrolysis, and related technologies could become precision tools for shaping reproducible peptide profiles and biological activity, enabling suppliers to develop more differentiated, outcome-oriented platforms.

Higher-Value Protein Systems. – As bioinformatics, peptidomics, AI, and high-throughput screening make peptide discovery more systematic, proteins may be valued for the functional outcomes they enable, creating new opportunities for existing ingredients, underused sources, and food-production side streams. Commercial value will depend on translating promising peptide systems into reproducible ingredients, substantiated benefits, and products consumers will trust and adopt.

What to Watch

Whether Specific Peptide Systems Can Demonstrate Meaningful Human Outcomes. – Watch for well-controlled human studies connecting defined peptides, effective doses, and delivery systems to meaningful, reproducible outcomes.

Whether Peptide Profiles Can Be Produced Consistently at Commercial Scale. – Watch for technologies and analytical methods that can reliably generate, characterize, and control defined peptides or reproducible peptide profiles across batches.

Whether Delivery Systems Can Preserve Biological Activity. – Watch for evidence showing which peptides remain active through processing and digestion and whether they reach their intended site of action at meaningful concentrations.

Whether Peptides Can Earn Commercial Permission in Viable Products. – Watch whether validated peptide systems strengthen familiar protein benefits such as recovery, satiety, connective-tissue support, and healthy aging or establish credible pathways into new outcome spaces. Commercial success will also require sensory quality, processing stability, practical dosing, credible claims, and formats consumers will use repeatedly.

FUNCTIONALFRONTIERS POINT OF VIEW

> Bioactive peptides could create a pathway from familiar protein benefits to more precisely designed functions and, ultimately, new outcome spaces. The opportunity begins with discovering promising peptide sequences, but it does not end there. Commercial success will depend on releasing, delivering, and validating peptide systems within food and beverage products that provide meaningful benefits and earn consumer trust and adoption.

Selected Sources

Chakrabarti, S., Jahandideh, F., & Wu, J. (2014). Food-derived bioactive peptides on inflammation and oxidative stress. *BioMed Research International, 2014*, 608979.

Amigo, L., & Hernández-Ledesma, B. (2020). Current evidence on the bioavailability of food bioactive peptides. Molecules, 25(19), 4479.

Sun, X., Acquah, C., Aluko, R. E., & Udenigwe, C. C. (2020). Considering food matrix and gastrointestinal effects in enhancing bioactive peptide absorption and bioavailability. Journal of Functional Foods, 64, 103680.

Daroit, D. J., & Brandelli, A. (2021). In vivo bioactivities of food protein-derived peptides: A current review. Current Opinion in Food Science, 39, 120-129.

Peredo-Lovillo, A., et al. (2022). Conventional and in silico approaches to select promising food-derived bioactive peptides: A review. Food Chemistry: X, 13, 100183.

Liu, B., et al. (2022). Review on the release mechanism and debittering technology of bitter peptides from protein hydrolysates. Comprehensive Reviews in Food Science and Food Safety, 21, 5153-5170.

Fekete, Á. A., Givens, D. I., & Lovegrove, J. A. (2015). Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients, 7(1), 659-681.

de Miranda, R. B., Weimer, P., & Rossi, R. C. (2021). Effects of hydrolyzed collagen supplementation on skin aging: A systematic review and meta-analysis. International Journal of Dermatology, 60(12), 1449-1461.

Simental-Mendía, M., et al. (2025). Effect of collagen supplementation on knee osteoarthritis: An updated systematic review and meta-analysis of randomised controlled trials. Clinical and Experimental Rheumatology, 43(1), 126-134.

Selected sources are provided to represent the scientific foundation of this brief. They are not intended to constitute a comprehensive systematic review.